Botanix builds Sofdra momentum, fortifies balance sheet and supply chain

Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an announcement.

Botanix reported continued growth in Sofdra prescriptions in the March quarter, with total prescriptions rising 5% to 26,684 and March delivering a record month as the U.S. hyperhidrosis market moves into the seasonally stronger summer period. Despite gross Sofdra sales holding steady at about $38 million, net revenue fell to $6.9 million due to a temporary gross‑to‑net compression linked to the annual insurance deductible reset that weighed on January and February sales.

Operating cash outflow increased to $23.3 million in the quarter, largely because of a scheduled $9.7 million purchase of active pharmaceutical ingredient, which lifted manufacturing costs but gives Botanix about $34.5 million of API inventory and removes the need for another major purchase until late 2027. The company strengthened its balance sheet with roughly $45 million in new equity and renegotiated its API supply deal and an alternate manufacturing arrangement with Piramal, moves that bolster supply security and support its growth ambitions while underlying operating and staff costs remain under disciplined control.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited is a clinical dermatology company listed on the ASX and headquartered in the United States. Its primary product is Sofdra, a sofpironium bromide topical gel for treating hyperhidrosis, targeting the U.S. dermatology and sweat disorder market.

Average Trading Volume: 20,547,030

Technical Sentiment Signal: Sell

Current Market Cap: A$89.77M

Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.